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 Introduction: 
Atrial fibrillation (AF), or AFib, is the most commonly occurring type of cardiac 
arrhythmia 1. AF is commonly referred to as an “irregularly irregular” rhythm and is defined 
as a supraventricular tachyarrhythmia in which an irregular electrical impulse in the upper 
chambers (atria) of the heart produces an uncoordinated depolarization and thus an inefficient 
contraction of the atria. As a result, there is a reduction in cardiac output and potential for 
pooling of blood in the atria which increases the risk of clot formation and mortality from a 
cerebrovascular accident or pulmonary embolism. AFib is a public health concern that affects 
up to 6 million people in the United States and is associated with more than 130,000 deaths 
per year. It also costs the U.S. healthcare system nearly $6 billion per year 2. AF becomes 
more prevalent with age, and with the steadily increasing elderly population worldwide, 
prevention and treatment of this condition becomes more important clinically and 
economically. Due to the immense burden on the healthcare system, there have been many 
advances in surgical and pharmacological modalities for treatment AF, however long-term 
anticoagulation therapy for prevention of thromboembolism has remained a guideline 
recommended treatment for AF. The goal of this article is to review the clinical aspects of 
atrial fibrillation including prevalence, pathophysiology, diagnosis, and treatment, with a 
focus on comparing traditional anticoagulation therapy of Warfarin with the newer non-
Vitamin K anti-coagulant Dabigatran (Pradaxa). This article will also serve to review 
recently collected data from the VA Medical Center in regard to implementation of 
anticoagulation guidelines in the management of non-valvular AFib. 
 
Epidemiology: 
 Heart disease and stroke statistics collected by the American Heart Association have 
shown that the prevalence and incidence of AF has been steadily increasing, and this trend is 
expected to continue.  As of 2010 approximately 2.6 to 6.1 million people in the United States 
have a diagnosis of AF, with that number estimated to reach as high as 12 million by 2050 3. 
Age, gender, race, lifestyle, and comorbid conditions all play a significant role in the lifetime 
prevalence of AF.  Studies have shown that the prevalence of AF increases as much as two-fold 
in men and women with each decade of life 4. The mean age at onset is 66.8 for men and 74.6 for 
women, with the point prevalence of AF increasing to more than 10% in the population over 80 
years old 1,3.  Men have consistently higher rates of AF compared to women throughout a 
majority of studies putting men at 1.5 times greater risk of AF 3,4. Multiples studies have also 
found that white people have significantly higher rate of AF when compared to blacks and other 
races, with white people accounting for more than 70% of AF related hospital admissions. 
Interestingly, the non-white races had higher rates of overall risk factors for developing AF 3,4.  
Data has consistently shown that the incidence of newly diagnosed AF has also followed the 
same trend and has been  highest among older white males, with the rates growing exponentially 
after 70 years of age across all genders and races 4. Many of these statistics are presumed to be 
underestimated due to undiagnosed cases of AF and patients who are asymptomatic or have only 
paroxysmal AF. Many of the current studies are also done with predominantly white populations 
5. 
 Additional factors outside of age, gender, and race that increase the lifetime risk of AF 
include lifestyle and comorbid conditions. Modifiable lifestyle factors that increase the risk of 
AF include smoking, alcohol, and obesity. Smoking is a known risk factor for increasing the 
likelihood of cardiovascular disease which increases the lifetime risk of developing AF. Multiple 
studies have shown that mild alcohol consumption does not significantly increase the likelihood 
of developing AF, however binge drinking and heavy alcohol consumption have been shown to 
be a risk factor. Cardiac arrhythmias, most commonly AF, associated with short periods of binge 
drinking is a phenomenon known as “holiday heart syndrome” and may be indicative of future 
cardiomyopathy 6. Multiple studies have shown that as many as 3 drinks per day, and heavy 
long-term alcohol consumption significantly increases the relative risk of AF 3,7. Although the 
exact pathophysiology is not known, obesity is considered a major risk factor for the 
development of AF, with a linear relationship existing in which there is a 4.7% increase in risk 
with each kilogram per square meter above average BMI 8.  Hypertension and coronary artery 
disease (CAD) are the most common chronic conditions associated with an increased risk of AF. 
Hypertension has been shown to increase the risk of AF 70% in women and 80% in men, even 
when the condition is properly treated 3. While CAD itself does not cause AF, an increased risk 
of developing AF is generally association with CAD with prior myocardial infarction (MI). This 
is thought to be caused by ischemia and structural damage to the heart in the setting of MI 9. 
Diabetes, chronic kidney disease, obstructive sleep apnea and hyperthyroidism have also been 
associated with increased incidence and prevalence of AF. There are multiple risk prediction 
models and online calculators, such as those found on the Framingham Heart Study website, that 
can be used by clinicians to help identify and reduce lifetime risk and mortality due to atrial 
fibrillation. 
 
Pathophysiology: 
 AF is a cardiac arrhythmia in which there is an uncoordinated electrical impulse 
generated in the upper chambers of the heart that causes an incomplete or inefficient contraction 
of the atria. The electrocardiogram (ECG) of AF is characterized by irregular R-R intervals, the 
absence of distinct P waves, and irregular atrial activity (Fig 1). Clinically, the ECG rhythm of 
AFib is referred to as irregularly irregular 2. Due to the lack of sufficient impulse and contraction 
in the atria, AF can cause hemodynamic instability from decreased cardiac output, as well as 
thrombotic events from stasis of blood in the atria.  
 AFib occurs when the combination of structural and electrophysiological abnormalities 
alters the normal functioning of the atrial heart tissue preventing a consistent electrical impulse 
(Fig 2). The exact mechanism that leads to AF is not well understood, however AF is thought to 
be the physical manifestation of multiple disease pathways that change the structure and function 
of the heart. Structural abnormalities that contribute to AF include fibrosis, dilation, ischemia, 
and hypertrophy, all of which are physical signs of damage caused by heart disease and various 
other health conditions. These disease processes produce structural remodeling, most 
significantly fibrosis, that decreases the heart tissue’s ability to generate and propagate an 
electrical impulse. The exact mechanism by which electrical impulses in the atria are altered is 
not well understood. Some research suggests that a potential trigger for AF may arise from 
rapidly firing foci that originate in the left atrium and into the pulmonary artery. Unique anatomy 
of the myocardial fibers within the veins may lead to a reentry impulse that triggers AF. This 
area is also the target of some surgical treatments for AF 10. 
 There are multiple types of AF which are classified by the duration of symptoms. The 
shortest and most benign type is paroxysmal AF, which involves intermittent episodes that 
generally resolve with or without treatment within 7 days of onset. Persistent AF is a sustained 
irregular rhythm that last greater than 7 days, although it may resolve later. Long-standing 
persistent AF lasts greater than 12 months and is refractory to treatment. Permanent AF is a 
subcategory of long-standing AF in which the patient and provider have tried all means of 
treatment and mutually decide to no longer attempt to restore a normal sinus rhythm 2. AF can 
also be classified is valvular or non-valvular, which is important when determining the proper 
type of anticoagulation therapy. The exact definition of valvular versus non-valvular AFib 
remains unclear, although it is important when considering anticoagulation therapy. Currently, 
valvular AF is associated with mitral stenosis, mechanical heart valves, and any valve repair, 
with non-valvular AFib including any valvular disease that does not limit the rate of blood flow 
to the left atrium such as mitral regurgitation or aortic stenosis, and AFib without valvular 
disease. 11. The distinction between valvular non-valvular is important because the guidelines 
recommend treatment of valvular AFib with vitamin K antagonists, whereas non-valvular can be 
treated with direct thrombin inhibitors as well 2.  
 
Presentation & Diagnosis: 
 The evaluation of a patient with suspected AF should include a thorough history to elicit 
the length and characteristics of symptoms to determine the classification of AF, and a complete 
physical examination to rule out other possible comorbidities and assess the need for emergent 
management. The history should cover the events preceding the onset of symptoms such as 
exercise, stress, or alcohol consumption in order to identify possible triggers or alternative causes 
of onset. Past medical history, symptoms, prior episodes with treatments, and family history 
should be reviewed to assess for associated cardiac and non-cardiac disease processes that may 
be contributing. A thorough history will help determine future prognosis, risk of thrombotic 
event, and treatment options. 12. 
 Patients with AF can have a wide spectrum of presentation from severe to completely 
asymptomatic, and is an incidental finding in 25-30% of cases 12. Patients with recurrent or 
paroxysmal types of AF are more likely to be symptomatic, although the described symptoms 
and physical exam findings can vary from patient to patient. In contrast, patients with permanent 
AF, particularly the elderly, often present with very few or no symptoms at all. The most 
common associated symptoms include palpitations, dyspnea, lightheadedness or dizziness, 
syncope, and chest pain/angina. Dyspnea is the most common symptom in chronic forms of AF 
(46.8%), and palpitations the most common with paroxysmal types of AF (79.0%) 12. 
 The presence of tachycardia, irregular pulses, variations in the intensity of S1 heart 
sounds, or absence of a previously heard 4th heart sound may be suggestive of a patient with AF. 
Many patients with AF may be presenting for the first time during an embolic event or heart 
failure, therefore the physical exam should include inspection for signs of neurovascular 
compromise or pulmonary and peripheral edema2.  
 The diagnosis of AF requires documentation of the arrhythmia with an electrocardiogram 
(ECG) (Fig. 1).  The recording can be done by a single-lead rhythm strip, 12-lead ECG, or 
ambulatory telemetry devices such as a Holter monitor. All patients with suspected AF should 
have a chest x-ray to evaluate for possible pulmonary pathology or cardiac enlargement. When 
AF is confirmed by ECG, patients should also receive a transesophageal echocardiograph (TEE) 
to identify cardiac abnormalities such as atrial or ventricular enlargement, pericardial disease, 
and to assess cardiac function. 12. TEE can also be useful in assessing for the presence of left 
atrial thrombus which would be a potential source of future emboli, and help guide the timing of 
cardioversion and catheter ablation. Prior to cardioversion, 5% - 15% of patients with AF have 
revealed a LA thrombus with TEE 2. 
 Additional laboratory testing that should be performed on patients with known or 
suspected AF include a complete blood count, serum electrolytes, liver and renal function, as 
well as thyroid function to rule out hyperthyroidism as a potential cause of arrhythmia. If more 
acute cardiac pathologies are suspected such as heart failure or infarction, the appropriate studies 
should also be ordered.  
 
Treatment: 
 Once a full evaluation, including a thorough history, physical exam, and diagnostic 
workup has been completed to and determine the type of AF and rule out potential underlying 
causes or risk factors, management options for AF should be considered. Management of AF 
includes modalities directly targeting the arrhythmia through rate and rhythm control, as well as 
anticoagulation therapy which mitigate the risk of a major thromboembolic event 13. The 
management of AF with therapy directed towards correcting the arrhythmia will be covered 
briefly here, though the focus of this article is anticoagulation therapy. 
 Strategies for managing AF focused on correction of the arrhythmia can be divided into 
rate control and rhythm control. Rate control consists of chronotropic drugs or 
electrophysiological ablation to reduce the ventricular rate of the heart. The guideline 
recommended heart rate (HR) goal is a resting HR less than 80 beats per minute (bpm), and less 
than 115 bpm during mild to moderate physical activity 2.  Medications recommended in the use 
of rate control include beta blockers, calcium channel blockers, digoxin, and amiodarone. Beta 
blockers and calcium channel blockers are used for patient without heart failure, whereas digoxin 
and amiodarone are recommended for those patients with AF and heart failure 2. Atrioventricular 
nodal ablation with a pacemaker implantation is a surgical procedure directed at rate control. 
While this option eliminates the need for rate control medications, it does require the permanent 
use of an implanted pacemaker as well as anticoagulation therapy.   
 The second approach in the management of AF arrhythmia is rhythm control. Rhythm 
control is accomplished through electrical cardioversion and pharmacological management. 
Rhythm control with AF is the preferred method of treatment because studies have shown that 
successful sinus rhythm maintenance is associated with improvements in symptoms and quality 
of life for most patients. It is the preferred treatment for younger patients, initial episodes of AF, 
or AF caused by comorbid illness. Direct current cardioversion is the most effective rhythm 
control method that consists of delivering an electrical shock synchronized to the QRS complex 
with the goal of restoring a normal sinus rhythm.  Pharmacological cardioversion is more 
effective when given within 7 days after onset. Intravenous administration of Ibutilide has been 
shown to restore sinus rhythm in up to 50% of patients within 30 minutes, however QT 
prolongation and torsades de pointes is associated with the use of these medications and can be 
potentially fatal 2.  
 
Anticoagulation Therapy: 
 The current guidelines by the American Heart Association, American College of 
Cardiology, and the Heart Rhythm Society (AHA/ACC/HRS) recommend that all patients with 
new onset AF undergo a risk stratification assessment and consideration for an oral 
antithrombotic medication regimen. The presence of AF can increase the risk of thromboembolic 
event such as stroke or myocardial infarction by up to 20 times compared to those with normal 
rhythms, and result in more severe disability and higher rates of mortality 14. Not every patient 
with AF will require anticoagulation therapy, and there is no single recommendation that is 
common to all patients. The decision to begin anticoagulation therapy should be a joint decision 
between the patient and provider that takes into consideration risk factors, lifestyle, medication 
type, cost, and side effects. The CHA2DS2-VASc score is the recommended tool for calculating 
risk of stroke and need for anticoagulation therapy 2,15.  
 The CHA2DS2-VASc risk stratification tool (Chart 2), or calculator, is used to determine 
the risk of stroke or thrombotic event in patients with AF and determine the need for 
anticoagulation therapy. The tool works by assigning a number value to known risk factors for 
stroke, including congestive heart failure, hypertension, age >75 years, diabetes, previous stroke, 
vascular disease, age 65-75 years, and female gender. Each factor is assigned a value of 1 point, 
while age >75 and previous stroke accounts for 2 points each. The total scores are then used to 
determine the overall risk and make recommendations for treatment based on the current 
recommended guidelines.  The most recent AHA/ACC/HRS guidelines for the treatment of non-
valvular AF recommend anticoagulation therapy, with Warfarin or Dabigatran, for all patients 
with prior stroke or CHA2DS2-VASc score >2. Patients with non-valvular AF and a CHA2DS2-
VASc score of 1 should be considered for anticoagulation therapy, and those with a score of 0, 
no anticoagulation therapy is needed 2. Once the risk of future thrombotic events and need for 
anticoagulation therapy has been determined, the patient and provider can consider the best 
medication to use for that individual. Antithrombotic medications reduce the risk of future stroke 
and emboli by preventing the formation of clots that may form in the atria due to the arrhythmia. 
One meta-analysis showed an average rate of stroke of just 4.1% per year for patients without 
previous stroke and 13% for patient with prior stroke, among patients treated with 
anticoagulation therapy 2,16. Common agents used for the prevention of thromboembolism 
include anticoagulants such as Heparin, Warfarin, and direct thrombin inhibitors, as well as 
antiplatelet drugs including Aspirin and Clopidogrel. This article will focus on Warfarin and the 
direct thrombin inhibitor Dabigatran. 
 
Warfarin: 
 Warfarin has been used to prevent stroke in patients with AF since the 1950’s. Warfarin, 
or Coumadin, is a vitamin K antagonist which works by preventing the synthesis of the vitamin 
K dependent clotting factors II, VII, IX, X, as well as protein C & S. During the synthesis of 
these clotting factors the enzyme vitamin K epoxide reductase complex 1 (VKORC1) reactivates 
vitamin K from an inactive form which is then used as a cofactor in the production of the clotting 
factors. Warfarin binds to the C1 subunit of the VKORC1 enzyme complex and prevents the 
reactivation of vitamin K, thus reducing the available vitamin K and synthesis of clotting factors. 
By reducing the amount of available clotting factors, there is a reduction in the ability to form a 
clot, thus decreasing the risk of thrombotic event and stroke 17–19.  
 The dosing of Warfarin should be individualized for each patient and take into 
consideration comorbid conditions and current state of the patient. While there are no current 
dosage adjustment recommendations for comorbid conditions, geriatric patients, those with 
renal, hepatic, or cardiac dysfunction, or those who are at increased risk of bleeding should be 
closely monitored. Warfarin has a very narrow therapeutic range and therefore requires strict 
adherence, regular monitoring, dosage adjustments, and dietary restrictions in order to remain 
safe and effective. The anticoagulation effect of Warfarin is monitored using a blood test that 
measures the prothrombin time and international normalized ratio referred to as the PT/INR. The 
target INR for AFib treated with Warfarin is 2.5 with a range of 2-3 2. When a patient’s INR is 
above this recommended range, they are at increased risk of major bleeding, and if it is below the 
recommended range they are at risk of a thromboembolic event, such as stroke, which the 
medication is indicated to prevent. In order to maintain within the therapeutic range it is 
recommended that patients have their INR checked two to three times per week upon starting the 
medication until they reach a therapeutic level, then every 1-4 weeks thereafter, dependent on 
their ability to maintain with the range 18,20. The determination of frequency of monitoring 
should take into consideration the patient’s preference, access, medication adherence, and past 
success maintaining within the therapeutic range. Initial dosing of Warfarin is 2 to 5 mg once 
daily, or 10 mg once daily for healthy patients with daily INR monitoring until the recommended 
target INR is achieved. The onset of action of Warfarin is 24 to 72 hours and the peak effect 
taking 5 to 7 days, therefore patients with an acute thromboembolism should be started on more 
rapidly acting Heparin with Warfarin started on the first or second day of treatment. Once a 
patient has reached the target INR they should be placed on maintenance therapy between 2 to 10 
mg per day in order to maintain within the range. It is also recommended that the medication be 
taken at a regular time each day without interruption. Inconsistency with medication adherence 
can cause large variations in INR and put the patient at risk of stroke or hemorrhage  17.  
 Due to Warfarin’s effect of preventing the formation of clots by lowering the amount of 
available clotting factors, there is inherently an increased risk of bleeding associated with its use. 
In fact, the increased risk of major bleeding defined as that which requires hospitalization, 
surgery, transfusion, or bleeding that occurs in the head, is the number one risk factor associated 
with the use of Warfarin as long-term anticoagulation therapy for AFib. The FDA has issued a 
Boxed Warning recognizing the increased risk of bleeding and recommending interventions to 
reduce the risk, including regular INR monitoring and immediately reporting any signs or 
symptoms of irregular bleeding 21. Multiple clinical trials and observational studies have shown 
that the overall risk of major bleeding associated with the use of Warfarin ranges between 1 to 3 
percent per person per year 13.  Of the most concern, due to its high rates of mortality and 
potential for long-term neurological disability, is intracranial hemorrhage (ICH), which accounts 
for up to 90% of deaths and permanent disability related to Warfarin-associated bleeding. The 
reported risk of ICH attributed to Warfarin therapy for AFib ranges between 0.2 to 0.4 percent 
per year, however this number may be higher dependent on additional patient risk factors. While 
the risk of major bleeding is increased, the overall risk of stroke while on adjusted-dose Warfarin 
therapy for AFib is reduced by two-thirds when compared to placebo or no therapy 22. The 
provider and patient must determine if the benefit offsets the potential risk with the 
anticoagulation therapy. They must also be counseled on the importance of regular dosing, 
monitoring, and reporting of anything that increases the risk of bleeding including accidents, 
falls, surgeries, changes to other medications, or eating habits.  
 In the event that a patient presents with a supratherapeutic INR(>4) without bleeding, the 
American College of Chest Physician Guidelines recommends lowering or withholding the dose 
until INR returns to normal and administration of oral vitamin K1 depending on the level of INR. 
If a patient experiences a major bleeding event the guidelines recommend discontinuation of the 
medication, administration of intravenous vitamin K1, and possible supplementation with four-
factor prothrombin complex concentrate (PCC). Other possible treatments include fresh frozen 
plasma and activated factor VII in urgent cases.  18,23. 
 Other considerations that should be taken into account when a patient is treated with 
Warfarin for AFib include dietary restrictions, alcohol consumption, and sports participation. 
The effectiveness of Warfarin and the ability to stay within the therapeutic INR range is greatly 
affected by dietary intake of vitamin K. While it is not recommended that patients refrain entirely 
from all foods rich in vitamin K, they should be educated on the vitamin K content of food and 
encouraged to maintain a consistent intake of vitamin K through their diet to maximize the 
therapeutic effect of the medication 17. The mechanism by which alcohol disrupts the effect of 
Warfarin is not completely understood, though studies have shown that the risk of major 
bleeding increases with moderate to severe alcohol consumption. As with dietary intake of 
vitamin K, patients should be encouraged to limit alcohol consumption and binge drinking while 
taking Warfarin 24. There are currently no recommendations or guidelines addressing activity 
level or participation in sports while on Warfarin, however the increased risk of severe bleeding 
is greater than that of the general population and the patient should be informed that a potential 
injury may be complicated by the increased risk of bleeding 17. 
 
Dabigatran: 
 For patients with non-valvular atrial fibrillation who require anticoagulation therapy and 
are unable to or elect not to take Warfarin, an alternative option is to choose from a class of 
anticoagulation medications referred to as newer, novel, or direct oral anticoagulants 
(NOAC/DOAC). These anticoagulation medications work on different sections of the clotting 
cascade than Warfarin while providing the same, if not better, therapeutic effect with less 
laboratory monitoring, and in some cases less risk of bleeding. Of these newer medications, 
Dabigatran was the first to be approved by the FDA in 2010 for the prevention of embolic stroke 
in patients with non-valvular AFib after the RE-LY study showed it to be non-inferior to 
Warfarin. Dabigatran is a competitive direct thrombin inhibiting prodrug that binds to thrombin 
(Factor IIa) and prevents the conversion of fibrinogen to fibrin and activation of platelet 
receptors and platelet aggregation. Once dabigatran is activated in vivo it binds to the active site 
of free, fibrin-bound, and clot-bound thrombin receptor sites preventing further activation of the 
clotting cycle and inducing its anticoagulation effects 25.   
The current recommended dose of Dabigatran for prevention of embolic stroke in patients 
with AFib is 150 mg twice daily, however the 2014 AHA/ACC/HRS guidelines recommend 
adjusted dosing for patients with chronic and end stage kidney disease. Patients with a creatinine 
clearance (CrCl) between 30-50 ml/min require no dosage adjustment unless concurrently 
prescribed Dronedarone or oral Ketoconazole, and those with CrCl of 15-30 ml/min should be 
adjusted to 75 mg twice daily. The AHA guidelines and the American College of Chest 
Physicians both recommend against the usage of Dabigatran in patients with severe renal 
dysfunction whose CrCl is less than 15 ml/min due to lack of evidence from clinical trials 2,26.  
Unlike Warfarin, Dabigatran produces consistent and linear dose-dependent anticoagulation 
properties that are not affected by the patient’s diet or activity, and therefore does not require 
regular laboratory monitoring or frequent dosage changes based on INR values25,26.  
Dabigatran has absolute contraindications for patients with a hypersensitivity to the drug 
or its components and those with pathological active bleeding. The 2014 AHA guidelines for 
management of patients with atrial fibrillation also has a class III for harm recommendation 
against the use of dabigatran for patients with a mechanical prosthetic heart valve 2,26. As with 
Warfarin, and all other anticoagulant medications, Dabigatran increases the risk of bleeding, 
although data from the RE-LY study and multiple meta analyses have shown that the risk of 
major bleeding including intracranial hemorrhage are less with Dabigatran when compared to 
Warfarin 27,28. The product labeling for Dabigatran does include a Boxed Warning concerning 
the increased risk of epidural and/or spinal hematomas which may occur in patients who undergo 
neuraxial anesthesia or spinal puncture procedures, and may result in long-term or permanent 
paralysis. It is recommended that these patients receive frequent monitoring of neurological 
symptoms in this setting 26,29. The most common side effect associated with the use of 
Dabigatran are gastrointestinal symptoms which can occur in 25-40% of patients 26.  
In 2015 the FDA approved the drug Idarucizumab (Praxbind) as a reversal agent for 
Dabigatran based on a preliminary report from the ongoing RE-VERSE AD study. Prior to the 
approval of Idarucizumab, many patients and providers were hesitant to choose Dabigatran over 
Warfarin for anticoagulation therapy because dabigatran does not respond to vitamin K and there 
was no reversal agent in the event of major hemorrhage due to accidental overdose or bleeding 
due to trauma. In August 2017 the final report from the RE-VERSE AD study based on 503 
patients treated with Idarucizumab to reverse the effects of dabigatran prior to a surgical 
procedure or in the event of major bleeding showed that a single 5 gram dose of the medication 
completely reversed the anticoagulation effect in 98% of patients for at least 24 hours 30. 
 
Warfarin vs. Dabigatran: 
 The risk of stroke is increased up to 5 times in patients with non valvular atrial 
fibrillation, and is attributed to higher rates of recurrent stroke and mortality, as well as more 
severe disability following a thrombotic event when compared to those with a normal sinus 
rhythm 2. Since the 1950’s, Warfarin has been the oral anticoagulation medication of choice until 
the FDA approval of Dabigatran in 2010. Multiple studies have shown that oral anticoagulation 
therapy is superior in the prevention of stroke as a primary outcome for patients with non 
valvular AFib, when compared to antiplatelet or no therapy at all 31. A 2007 meta-analysis that 
reviewed 29 randomized controlled trials comparing adjusted dose Warfarin to placebo and 
antiplatelet therapy showed that Warfarin was nearly 40% more effective in preventing stroke 
than antiplatelet therapy alone. Warfarin reduced the risk of stroke by 64% (95% CI: 49% to 
74%) with an absolute risk reduction of 2.7% per year with the number needed to treat to prevent 
1 stroke in one year of 37 16. These results have been consistent across multiple trials and 
reviews.  
 The efficacy and safety of Dabigatran for use in patients with AFib on long term 
anticoagulation therapy was compared to Warfarin in the RE-LY (Randomized Evaluation of 
Long Term Anticoagulation Therapy) trial in 2009 2. The RE-LY trial included 18,113 patients 
with AFib and an increased risk of stroke who were randomly assigned Dabigatran at 110mg and 
150mg doses or adjusted dose Warfarin, and had a primary outcome of stroke or systemic 
embolism. All patients were randomly assigned a treatment group with each dose of Dabigatran 
(110mg/150mg) double blinded and Warfarin being open label and unblinded. The mean age of 
the participants was 71 years, with 63.6% male, and the mean CHADS2 score being 2.1. The 
mean follow-up period was 2.0 years with a 99.9% follow up rate and only 20 patients lost to 
follow up 32.  
 The results of the RE-LY trial showed that Dabigatran dosed at 110mg was non-inferior 
to Warfarin in prevention of stroke and systemic embolism, and showed lower rates of life 
threatening hemorrhage. Dabigatran dosed at 150mg showed significantly lower rates of stroke 
and embolism with similar rates of bleeding when compared to Warfarin. In the primary 
outcome of stroke, Warfarin had a rate of 1.69% per year compared to 1.53% for the 110mg 
Dabigatran group (RR 0.91; 95% CI 0.74 to 1.11; P<0.001 for non-inferiority) and 1.11% for the 
150mg group (RR 0.66; 95% CI, 0.53 to 0.82; P<0.001 for superiority) 32. Both doses of 
Dabigatran were found to be non-inferior to Warfarin however the 150mg dose was superior to 
dose adjusted Warfarin. The primary safety outcome studied was major bleeding defined as a 
reduction in hemoglobin level of at least 20g/L, transfusion of at least 2 units of blood, or 
symptomatic bleeding in a major organ or critical region. Warfarin had a major bleeding rate of 
3.36% per year, and both the 110mg and 150mg doses of Dabigatran showed lower rates of 
2.71% and 3.11% respectively 32. The secondary outcomes included both hemorrhagic stroke and 
mortality with both doses of Dabigatran having significantly lower rates when compared to 
Warfarin. The rate of hemorrhagic stroke in patients on each dose of Dabigatran was nearly 75% 
less than that of Warfarin, with the 150mg dose of Dabigatran having lower rates than the 110mg 
dose 2. The rates of mortality for Warfarin, 110mg and 150 mg Dabigatran were 4.13%, 3.75%, 
and 3.64% respectively 32. The study also showed that Warfarin had higher rates of life 
threatening bleeding, intracranial bleeding, and minor bleeding when compared to each dose of 
Dabigatran, however there was a significantly higher rate of gastrointestinal bleeding with the 
150mg dose of Dabigatran. Also, each dose of Dabigatran had higher rates of myocardial 
infarction compared to Warfarin (150mg – 0.75%, 110mg – 0.72%, Warfarin – 0.53%) 32.  
 
Discussion: 
 The results of the RE-LY trial revealed that Dabigatran dosed at 150mg twice per day 
was superior to Warfarin in stroke prevention without an increase in major bleeding or 
intracranial hemorrhage in patients with non-valvular AFib. These finding have been reproduced 
in multiple studies across multiple age groups with all variations of AFib. The 2014 American 
Heart Association guidelines for the management of non-valvular atrial fibrillation recommends 
the use of both dose adjusted Warfarin and 150mg dose Dabigatran for anticoagulation therapy. 
Both are Class A recommendations however Warfarin is a level A and Dabigatran is a level B 
due to much more available research on Warfarin 2. The 2012 American College of Chest 
Physicians guidelines for antithrombotic therapy for atrial fibrillation recommends Dabigatran 
150mg twice daily in favor of dose adjusted Warfarin for stroke prevention with AFib 33.  
Both Warfarin and Dabigatran are acceptable and guideline recommended options for 
anticoagulation therapy and stroke prevention with AFib. The decision on which medication to 
choose should be a joint decision-making process between the patient and provider that takes 
into consideration multiple factors including potential risk of major or life-threatening bleeding, 
potential side effects, patient lifestyle and adherence ability, and cost as well as the providers 
experience using one medication over another. Dabigatran is more regularly dosed and does not 
require frequent blood monitoring or dosage adjustments, which may lead to better medication 
adherence when compared to Warfarin. It also has no dietary restrictions, less drug interactions, 
and poses less risk of major bleeding. Dabigatran also has more gastrointestinal side effects, and 
until recently, a major concern for some patients has been the lack of reversal agent for 
Dabigatran in case of bleeding emergency.  While Warfarin has a higher risk of major bleeding 
compared to Dabigatran, it has been a reliable and effective medication for many years and is a 
medication that both patients and providers are familiar with and comfortable using. Warfarin 
also has lower rates of non-bleeding side effects and a lower risk of myocardial infarction 
compared to Dabigatran. In many cases the most influential factor in choosing an anticoagulation 
medication is cost. Currently the cost of Dabigatran is much higher than Warfarin with 150mg 
Dabigatran $7.42 per dose and Warfarin $3.71 per 10mg dose 20,26. These costs are strictly the 
per dosage cost for each medication and do not take into account the overall cost including office 
visits, laboratory testing, and hospital visits. A study from the Journal of Medical Economics in 
2015 presented that the overall medical cost of those on Dabigatran was $204 less per year than 
those on Warfarin for anticoagulation therapy and they predict the medical cost difference to 
increase by 2018 34. Once it is determined that a patient meets criteria for anticoagulation therapy 
based on their risk stratification, careful consideration should be given to all of these factors, and 
the patient should be provided all of the benefit-to-risk information so that they may make an 
informed logical decision.  
 
Anticoagulation Therapy at the VA: 
 Treating patients at a VA medical center is a unique clinical experience with a 
challenging patient population that can alter the medical decision-making process and ultimately 
change the way a provider implements guideline recommended therapy. This is especially true 
when considering anticoagulation therapy for veterans with non-valvular atrial fibrillation. VA 
statistics show that the median age of the veteran patient population is higher than that of the 
non-veteran population (64 years to 44 years respectively), and the number of significant 
comorbid medical conditions, including mental health, is higher among the veteran population 
compared to non-veterans 35,36. Many of these veterans may also have a physical disability that 
limits their mobility or ability to drive and leave their homes. Because veterans can only receive 
care at VA facilities, some patients who do not live near a VA medical center may need to travel 
long distances for regular care, and thus might only seek care in an emergency. All of these 
factors can increase the risk of a veteran patient acquiring atrial fibrillation or having potentially 
serious or life-threatening complications, making the anticoagulation treatment decision more 
complex. Another important factor is cost. Veterans receive care at the VA free of cost, or at a 
highly discounted rate, which can change the anticoagulation therapy decision. As was discussed 
earlier, the cost of Dabigatran is much greater than that of Warfarin, therefore a patient who 
prefers to be on the latter may decide to receive his care from the VA in order to get the 
medication free of cost.  
 Recently, the Home Based Primary Care (HBPC) team at the Durham VA medical center 
conducted a quality control study to look at the implementation of guideline recommended 
anticoagulation therapy for veteran patients with non-valvular atrial fibrillation. Their main 
objective was to determine if the Veteran patients with AFib receiving home based primary care 
are on guideline appropriate antithrombotic therapy (either Warfarin or novel anticoagulant; not 
aspirin alone). The HBPC team also wanted to examine why a veteran was, or was not, adherent 
to guidelines, why they were on a particular medication over another, and how they could 
improve compliance to the guidelines. The team used the 2014 AHA/ACC/HRS Guideline for 
the Management of Patients with Atrial Fibrillation as their recommendations for therapy. The 
study included 190 of the home based primary care patients who receive all of their non-
emergent medical care by a team of providers that come to their home at least once per month. 
Each patient’s CHA2DS2VASc score was calculated and a chart review was conducted to 
determine current anticoagulation therapy, reason for currently recommended therapy, and 
comorbid conditions 37.  
 The results of the study showed that 20% (39/190) of the HBPC patients had a diagnosis 
of AFib. The average age was 81 years with a range of 64-94 years, and a CHA2DS2VASc score 
of 5 being the most common. The increased age and high CHA2DS2VASc score put these 
patients at very high risk of a thromboembolic event and anticoagulation therapy was indicated. 
Of the 39 patients being treated for AFib, 82% were prescribed Warfarin or a direct 
thrombin/factor Xa inhibitor such as Dabigatran, and were considered adherent to antithrombotic 
guidelines (Fig 3). Of the remaining 7 patients who were not being treated with adequate 
anticoagulation therapy and considered non-adherent to guideline recommendations, 4 had 
history of recurrent or life-threatening bleeds, 2 were medication refusal by patients or family, 
and one had history of medication non-adherence due severe dementia 37.   
 While the sample population in this study was small, it indicated that the overall 
compliance of the HBPC team to antithrombotic guidelines was good, and the reasons for non-
adherence were clinically acceptable. It also showed that the decision to treat a patient with 
anticoagulation therapy and what medication to use can become very complex when taking into 
account advancing age, comorbid conditions, and mental status. The HBPC program poses a 
unique set of complications when deciding between Warfarin or Dabigatran for anticoagulation 
therapy. These patients are severely ill or disabled and are only seen by healthcare providers 
once a month. With these patients, it is hard to frequently monitor INR values in order to 
maintain within the therapeutic INR window, and there is also a question of the accuracy of the 
handheld point of care testing machines. On the other hand, a patient who might be at higher risk 
of medication non-adherence who is already on Warfarin, switching to a NOAC provides no way 
to monitor the anticoagulation effects, which may make them a poor candidate for Dabigatran 
despite easier dosing. The HBPC team’s study suggests that guideline adherence for 
anticoagulation therapy at the VA medical center is a complex issue that warrants further 
examination for the health and safety of veteran population 37.  
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Appendix 
 
Chart 1. Clinical Comparison of Warfarin and Dabigatran 
 
 
Chart 2. CHA2DS2-VASc Calculation 
 
  
 
 
 
 
Clinical Consideration Warfarin Dabigatran 
Valvular or Non-Valvular Valvular & Non-Valvular Non-Valvular 
Cost $3.71 / 10mg $7.41 / 150mg 
Side Effects Few Gastrointestinal  
Dosing 2-10mg Adjusted to INR 150mg Twice per day 
Monitoring Every 1-4 weeks  None Recommended 
Dietary Restrictions Stable Vitamin K1 Intake None Recommended 
Bleeding Risk (RE-LY) 3.36% / year 3.11% / year 
Rate of Stroke / yr. (RE-LY) 1.69% / year 1.11% / year 
Reversal Agent Vitamin K Idarucizumab 
Drug/Drug Interactions 850 (213 major) 390 (118 major) 
Precautions (Dosage 
Adjustments) 
INR Dependent CrCl <30 mL/min – 75mg 
twice per day 
Mechanism of Action Vitamin K antagonist Direct Thrombin Inhibitor 
Category Score 
Congestive Heart Failure 1 
Hypertension 1 
Age >75 2 
Diabetes Mellitus 1 
Stroke/TIA 2 
Vascular Disease (Prior MI, PAD, aortic 
plaque) 
1 
Age 65-74 years 1 
Female Gender 1 
Fig. 1. Atrial Fibrillation ECG Rhythm Strip.   
 
Fig 2.  
 
 
 
Fig 3. 
 
 
Search Methods: 
 A PubMed search was completed using the key words atrial fibrillation, Warfarin, 
Dabigatran, and anticoagulation therapy. Additional search terms included Warfarin versus 
Dabigatran, reversal agent for warfarin and dabigatran, and treatment guidelines for atrial 
fibrillation. An UpToDate search was also completed using the key words atrial fibrillation, 
Warfarin, and Dabigatran. In order to obtain additional articles for this clinical review a 
reference search of the systematic reviews and treatment guidelines identified during the primary 
PubMed and UpToDate searches was used to identify additional pertinent articles. 
 
 
 
 
82% 
18% 
HBPC	Adherence	to	Antithrobmotic	Therapy	for	Atrial	
Fibrillation
Adherent	(N=32) Non-Adherent	(N=7)
Cochrane Tool for Risk of Bias: 
Risk of bias in the included studies with respect to sequence generation, allocation concealment, 
blinding, incomplete outcome data, and selective reporting was assessed using the Cochrane 
Collaboration’s risk-of-bias assessment tool 
 
Study 
Random 
Sequence 
Generation 
Allocation 
Concealment 
Blinding of 
Participants 
and 
Personnel 
Blinding of 
outcome 
assessment 
Incomplete 
Outcome 
Data 
Selective 
Reporting 
Other 
Bias 
Hylek 
2014 Unclear Unclear Low Low Low Low Low 
Connolly 
2009 Low Low High Low Unclear Low Low 
 
 
 
 
 
 
 
